Stock Track | Phathom Pharmaceuticals Stock Soars Pre-Market on Impressive Q3 Results

Stock Track11-07

Shares of Phathom Pharmaceuticals (NASDAQ: PHAT) soared over 5% in pre-market trading today, following the company's release of its third-quarter 2024 financial results that handily beat Wall Street expectations.

For the quarter ended September 30, 2024, Phathom reported an adjusted net loss of $1.05 per share, significantly better than the consensus analyst estimate of a $1.50 loss per share. The company's revenue came in at $16.352 million, surpassing the $12.609 million analysts had projected.

The strong quarterly performance appears to have fueled investor optimism, driving Phathom's stock higher in early trading. The biopharmaceutical company's ability to exceed earnings and revenue forecasts signals its continued growth trajectory and strengthening financial position.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1169774213?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-07 21:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1169774213","market":"us","top_or_hot":-1,"title":"Stock Track | Phathom Pharmaceuticals Stock Soars Pre-Market on Impressive Q3 Results","media":"Stock Track","content":"<p>Shares of Phathom Pharmaceuticals (NASDAQ: PHAT) soared over 5% in pre-market trading today, following the company's release of its third-quarter 2024 financial results that handily beat Wall Street expectations.</p>\n\n<p>For the quarter ended September 30, 2024, Phathom reported an adjusted net loss of $1.05 per share, significantly better than the consensus analyst estimate of a $1.50 loss per share. The company's revenue came in at $16.352 million, surpassing the $12.609 million analysts had projected.</p>\n\n<p>The strong quarterly performance appears to have fueled investor optimism, driving Phathom's stock higher in early trading. The biopharmaceutical company's ability to exceed earnings and revenue forecasts signals its continued growth trajectory and strengthening financial position.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Phathom Pharmaceuticals Stock Soars Pre-Market on Impressive Q3 Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Phathom Pharmaceuticals Stock Soars Pre-Market on Impressive Q3 Results\n</h2>\n\n<h4 class=\"meta\">\n\n2024-11-07 21:10 北京时间&nbsp;&nbsp;&nbsp;<strong>Stock Track</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of Phathom Pharmaceuticals (NASDAQ: PHAT) soared over 5% in pre-market trading today, following the company's release of its third-quarter 2024 financial results that handily beat Wall Street ...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PHAT","symbol_name":"Phathom Pharmaceuticals","start_time":0,"source_url":"","article_id":"1169774213","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1169774213","pubTimestamp":1730985022,"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Phathom Pharmaceuticals  soared over 5% in pre-market trading today, following the company's release of its third-quarter 2024 financial results that handily beat Wall Street expectations.For the quarter ended September 30, 2024, Phathom reported an adjusted net loss of $1.05 per share, significantly better than the consensus analyst estimate of a $1.50 loss per share. The company's revenue came in at $16.352 million, surpassing the $12.609 million analysts had projected.The strong qua","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PHAT":"Phathom Pharmaceuticals"},"translate_title":"股票追踪Phathom Pharmaceuticals股价因第三季度业绩令人印象深刻而盘前飙升","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PHAT":1},"content_text":"Shares of Phathom Pharmaceuticals (NASDAQ: PHAT) soared over 5% in pre-market trading today, following the company's release of its third-quarter 2024 financial results that handily beat Wall Street expectations.\nFor the quarter ended September 30, 2024, Phathom reported an adjusted net loss of $1.05 per share, significantly better than the consensus analyst estimate of a $1.50 loss per share. The company's revenue came in at $16.352 million, surpassing the $12.609 million analysts had projected.\nThe strong quarterly performance appears to have fueled investor optimism, driving Phathom's stock higher in early trading. The biopharmaceutical company's ability to exceed earnings and revenue forecasts signals its continued growth trajectory and strengthening financial position.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1169774213"}